Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Relapsing Polychondritis: early-phase trial registry
3 of 4 indexed Relapsing Polychondritis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Relapsing Polychondritis: 4 US clinical trials tracked, 3 recruiting.
Relapsing Polychondritis is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is University of Pennsylvania, running 2 of these trials.
Enrollment posture brief
Registry condition relapsing-polychondritis
OPEN 3 | RECR 75% | LATE 0 | EARLY 2 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Relapsing Polychondritis lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Relapsing Polychondritis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Relapsing Polychondritis is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NCT02257866
Longitudinal Study for Relapsing Polychondritis
University of Pennsylvania
NCT04919538
An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis
University of Pennsylvania
NCT06941376
Study on the Safety of Abatacept in Relapsing Polychondritis
Benaroya Research Institute
NCT01272856
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Relapsing Polychondritis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Relapsing Polychondritis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Relapsing Polychondritis page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Relapsing Polychondritis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Pennsylvania sponsors the most Relapsing Polychondritis trials on record, review their full trial history before evaluating a specific study. See University of Pennsylvania's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Relapsing Polychondritis condition card totals 4 registered trials; most-linked intervention Abatacept; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.